535 related articles for article (PubMed ID: 24562650)
1. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
[TBL] [Abstract][Full Text] [Related]
2. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
[TBL] [Abstract][Full Text] [Related]
3. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
4. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT.
Ak İ; Onner H; Akay OM
Ann Hematol; 2015 Sep; 94(9):1567-75. PubMed ID: 26068066
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of
Sachpekidis C; Hillengass J; Goldschmidt H; Anwar H; Haberkorn U; Dimitrakopoulou-Strauss A
Am J Nucl Med Mol Imaging; 2017; 7(4):148-156. PubMed ID: 28913153
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging.
Minamimoto R; Mosci C; Jamali M; Barkhodari A; Habte F; Jackson T; Mittra E; Gambhir SS; Iagaru A
J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978
[TBL] [Abstract][Full Text] [Related]
8. Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study.
Sachpekidis C; Thieke C; Askoxylakis V; Nicolay NH; Huber PE; Thomas M; Dimitrakopoulou G; Debus J; Haberkorn U; Dimitrakopoulou-Strauss A
Am J Nucl Med Mol Imaging; 2015; 5(2):127-42. PubMed ID: 25973334
[TBL] [Abstract][Full Text] [Related]
9. Can
Sachpekidis C; Kopp-Schneider A; Merz M; Jauch A; Raab MS; Goldschmidt H; Dimitrakopoulou-Strauss A
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456181
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
11. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
[TBL] [Abstract][Full Text] [Related]
12. Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases.
Simoncic U; Perlman S; Liu G; Staab MJ; Straus JE; Jeraj R
Clin Genitourin Cancer; 2015 Feb; 13(1):e7-e17. PubMed ID: 25128349
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using
Nakuz TS; Millinger FP; El-Rabadi K; Weber M; Pichler V; Wadsak W; Mitterhauser M; Haug A; Hacker M; Karanikas G; Pietschmann P; Agis H
Anticancer Res; 2019 Apr; 39(4):1943-1952. PubMed ID: 30952737
[TBL] [Abstract][Full Text] [Related]
14. Different lesions revealed by 18F-FDG PET/CT and 18F-NaF PET/CT in patients with multiple myeloma.
Xu F; Liu F; Pastakia B
Clin Nucl Med; 2014 Sep; 39(9):e407-9. PubMed ID: 24217536
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
Iagaru A; Mittra E; Dick DW; Gambhir SS
Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer.
Sachpekidis C; Kopka K; Eder M; Hadaschik BA; Freitag MT; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2016 Nov; 41(11):e473-e479. PubMed ID: 27607173
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG and 18F-NaF PET/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement.
Oral A; Yazici B; Ömür Ö; Comert M; Saydam G
Clin Nucl Med; 2015 Nov; 40(11):873-6. PubMed ID: 26204214
[TBL] [Abstract][Full Text] [Related]
18. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
[TBL] [Abstract][Full Text] [Related]
19. Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer.
Simoncic U; Perlman S; Liu G; Jeraj R
Nucl Med Commun; 2015 Dec; 36(12):1174-80. PubMed ID: 26378490
[TBL] [Abstract][Full Text] [Related]
20. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
